Viromed Medical AG, a medical technology company specializing in cold plasma technology, has announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. The physicist and expert in spectroscopy brings extensive scientific knowledge in the fields of spectroscopy and materials research to the board.
Uwe Perbandt, CEO of Viromed Medical AG, expressed enthusiasm about the appointment, stating: "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work."
Prof. Dr. Rubhausen heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as the Institute's Managing Director. He is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research focuses on modern spectroscopic methods, including Raman spectroscopy and ellipsometry, which he uses to study superconductors, quantum materials, and biological and inorganic samples at large-scale research facilities such as PETRA III and FLASH.
His interdisciplinary scientific work includes more than 180 publications with approximately 4,000 citations, contributing to renowned scientific journals like Physical Review Letters, JACS, Angewandte Chemie, Nature Chemistry, Nature Physics, Cellular and Molecular Life Sciences, and Nature Communications. Additionally, his work involves developing AI-supported analysis workflows for complex, high-dimensional datasets.
This appointment underscores Viromed's commitment to advancing its research and development in cold plasma technology. By integrating Prof. Dr. Rubhausen's expertise in spectroscopy and materials research, the company aims to deepen its understanding of the interactions between plasma and biological materials, potentially leading to innovative medical applications.
Cold plasma technology, which Viromed specializes in, is emerging as a promising tool in medicine for applications such as wound healing, disinfection, and cancer treatment. The technology works by generating reactive species that can interact with biological tissues, offering potential therapeutic benefits.
For more information about Viromed Medical AG, visit their website at www.viromed-medical-ag.de.
